Breaking News Instant updates and real-time market news.

PFPT

Proofpoint

$71.02

-2.4 (-3.27%)

, FTNT

Fortinet

$34.09

-0.9 (-2.57%)

10:42
10/12/16
10/12
10:42
10/12/16
10:42

Proofpoint selloff brings good entry point, says Wedbush

Wedbush analyst Steve Koenig believes today's selloff in shares of Proofpoint (PFPT) presents a good entry opportunity. The analyst does not view Fortinet (FTNT), which last night preannounced weaker than expected results, as a bellwether for the network security space. Koenig adds Barracuda Networks (CUDA) last night attributed its earnings beat to traction with new cloud-based offerings. The analyst keeps an Outperform rating on Proofpoint.

PFPT

Proofpoint

$71.02

-2.4 (-3.27%)

FTNT

Fortinet

$34.09

-0.9 (-2.57%)

CUDA

Barracuda

$25.98

2.6549 (11.38%)

  • 20

    Oct

  • 27

    Oct

  • 14

    Nov

  • 12

    Dec

PFPT Proofpoint
$71.02

-2.4 (-3.27%)

07/25/16
IMPC
07/25/16
NO CHANGE
Target $69
IMPC
Outperform
Proofpoint guidance looks conservative, says Imperial Capital
Imperial Capital analyst Michael Kim thinks Proofpoint's initial FY17 revenue guidance appears conservative given the company's multiple growth drivers and his expectations for larger archiving transactions. The firm keeps an Outperform rating and $69 price target on Proofpoint shares.
07/26/16
IMPC
07/26/16
NO CHANGE
Target $83
IMPC
Outperform
Proofpoint price target raised to $83 from $69 at Imperial Capital
Imperial Capital analyst Michael Kim raised his price target for Proofpoint to $83 citing a higher outlook following the company's Q2 results. The analyst thinks management's initial FY17 revenue guidance appears relatively conservative and he keeps an Outperform rating on the name.
08/01/16
NEED
08/01/16
INITIATION
Target $88
NEED
Buy
Proofpoint initiated with a Buy at Needham
Target $88.
10/04/16
DADA
10/04/16
INITIATION
Target $80
DADA
Neutral
Proofpoint initiated with a Neutral at DA Davidson
DA Davidson analyst Kevin Reevey initiated Proofpoint with a Neutral and an $80 price target due to premium valuation.
FTNT Fortinet
$34.09

-0.9 (-2.57%)

10/12/16
10/12/16
DOWNGRADE
Target $32

Equal Weight
Fortinet downgraded to Equal Weight at Stephens
As previously reported, Stephens analyst Jonathan Ruykhaver downgraded Fortinet to Equal Weight from Overweight after the company announced "disappointing" preliminary Q3 results with an expected billings range of $343M-$348M versus consensus of $375M. The analyst believes that in addition to slower overall growth in the network security market, heightened competition is impacting sales growth. He also lowered his price target on the shares to $32 from $43.
10/12/16
SPHN
10/12/16
DOWNGRADE
SPHN
Equal Weight
Fortinet downgraded to Equal Weight from Overweight at Stephens
10/12/16
10/12/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Norfolk Southern (NSC) downgraded to Underperform from Market Perform at Avondale with Donald Broughton saying he continues to believe volumes will continue to decline, yields will continue to disappoint, cost savings will be increasingly harder to achieve, return on invested capital will continue to deteriorate, and the combination of those factors should result in fiscal 2017 earnings below fiscal 2016, pressuring valuation. 2. Fortinet (FTNT) downgraded to Equal Weight from Overweight at Stephens with analyst Jonathan Ruykhaver saying he believes that in addition to slower overall growth in the network security market, heightened competition is impacting sales growth. 3. Alcoa (AA) downgraded to Neutral from Buy at BofA/Merrill with analyst Timna Tanners saying she believes Alcoa's aerospace-focused downstream segment will continue to struggle with execution issues and delays over the next several quarters. 4. Emerson (EMR) downgraded to Sell from Neutral at UBS with analyst Shannon O'Callaghan saying analysts need to lower estimates to reflect Emerson's portfolio transformation, pension headwinds and end market pressures. 5. Nanometrics (NANO) downgraded to Sector Weight from Overweight at Pacific Crest with analyst Weston Twigg saying 3D NAND equipment demand is likely to peak in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/16
UBSW
10/12/16
NO CHANGE
Target $40
UBSW
Buy
Fortinet positive fundamentals remain unchanged, says UBS
UBS analyst Brent Thill noted Fortinet pre-announced negative earnings and attributed the miss to sales execution challenges in the U.S. Thill said his positive fundamental view on Fortinet's core technology remains unchanged and sees the company's problems as fixable. Thill maintained his Buy rating and lowered his price target to $40 from $42 on Fortinet shares.
CUDA Barracuda
$25.98

2.6549 (11.38%)

10/12/16
PIPR
10/12/16
UPGRADE
Target $32
PIPR
Overweight
Barracuda upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski upgraded Barracuda Networks to Overweight saying the company reported "another strong quarter." Its transition to a subscription-based cloud portfolio is nearly complete, Nowinski tells investors in a research note. He expects Barracuda's billings growth to accelerate in the second half of FY17 and upped his price target for the shares to $32 from $18.
10/12/16
SPHN
10/12/16
NO CHANGE
Target $24
SPHN
Equal Weight
Barracuda price target raised to $24 from $18 at Stephens
Stephens analyst Jonathan Ruykhaver raised his price target for Barracuda to $24 from $18 after the company reported Q2 results that "meaningfully" beat on revenue, earnings, and gross billings. The analyst reiterates an Equal Weight rating on the stock.
10/12/16
10/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Positive from Negative at OTR Global with the firm saying its checks indicate iPhone 7 launch orders are above last year's model launch, with fourth quarter order gains and stable inventories. 2. Procter & Gamble (PG) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's plans to accelerate Research & Development and advertising spending, as well as recent positive earnings surprises. 3. Barracuda (CUDA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Andrew Nowinski saying the company reported "another strong quarter" and its transition to a subscription-based cloud portfolio is nearly complete. 4. AMD (AMD) upgraded to Neutral from Underperform at Credit Suisse with analyst John Pitzer saying near-term momentum will continue to offset longer-term concerns around lack of scale. 5. Motorola Solutions (MSI) upgraded to Outperform from Market Perform at BMO Capital with analyst Tim Long saying he expects organic revenue growth to return later this year and sees the company's investment in smart public safety software to help expansion beyond hardware. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/16
STFL
10/12/16
NO CHANGE
Target $32
STFL
Buy
Barracuda price target raised to $32 from $26 at Stifel
Stifel analyst Gur Talpaz raised Barracuda's price target to $32 from $26 following the Q2 beat and raised FY17 guidance. The analyst said Barracuda had meaningful traction in core products and continues to achieve with its email security and public cloud solutions with both new and existing customers. Additionally, the initial demand for the company's core product line not only translates to growth in core billings but in core subscription ARR, which increased 50% year-over-year to $146mn during the period, the analyst wrote. Talpaz believes the growth opportunity for Barracuda's email security and public cloud solutions to be large and reiterates his Buy rating.

TODAY'S FREE FLY STORIES

MEI

Methode Electronics

$40.10

1.45 (3.75%)

07:54
06/23/17
06/23
07:54
06/23/17
07:54
Recommendations
Methode Electronics analyst commentary  »

Baird remains a buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNHPF

Hon Hai Precision

, TOSYY

Toshiba, also use TOSBF

$17.39

0.085 (0.49%)

07:53
06/23/17
06/23
07:53
06/23/17
07:53
Periodicals
Foxconn's Gou still sees 50% chance of landing Toshiba chip unit, DigiTimes says »

Foxconn (HNHPF) Chairman…

HNHPF

Hon Hai Precision

TOSYY

Toshiba, also use TOSBF

$17.39

0.085 (0.49%)

TOSBF

Toshiba, also use TOSYY

$2.88

-0.01 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$35.36

0.48 (1.38%)

07:53
06/23/17
06/23
07:53
06/23/17
07:53
Hot Stocks
AstraZeneca announces positive CHMP opinion for Faslodex »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

V

Visa

$93.95

-0.59 (-0.62%)

07:52
06/23/17
06/23
07:52
06/23/17
07:52
Recommendations
Visa analyst commentary  »

Visa a good idea for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$19.88

0.38 (1.95%)

07:51
06/23/17
06/23
07:51
06/23/17
07:51
Technical Analysis
Technical View: Cara Therapeutics at new 52-week high in pre-market »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

KMX

CarMax

$62.50

2.76 (4.62%)

07:51
06/23/17
06/23
07:51
06/23/17
07:51
Recommendations
CarMax analyst commentary  »

CarMax weakness on sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 30

    Jun

07:50
06/23/17
06/23
07:50
06/23/17
07:50
General news
Treasury Market Outlook: bonds are mixed while stocks are mostly lower »

Treasury Market Outlook:…

ENTA

Enanta

$37.11

1.77 (5.01%)

, ABBV

AbbVie

$73.18

1.84 (2.58%)

07:49
06/23/17
06/23
07:49
06/23/17
07:49
Hot Stocks
Enanta announces AbbVie recieves CHMP positive opinion for MAVIRET »

Enanta Pharmaceuticals…

ENTA

Enanta

$37.11

1.77 (5.01%)

ABBV

AbbVie

$73.18

1.84 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIC

Otonomy

$17.75

0.25 (1.43%)

07:48
06/23/17
06/23
07:48
06/23/17
07:48
Recommendations
Otonomy analyst commentary  »

Otonomy trial has high…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$56.23

0.27 (0.48%)

07:45
06/23/17
06/23
07:45
06/23/17
07:45
Recommendations
Harley-Davidson analyst commentary  »

Harley-Davidson retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 02

    Oct

HAIN

Hain Celestial

$32.66

-0.5 (-1.51%)

, AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

07:44
06/23/17
06/23
07:44
06/23/17
07:44
Recommendations
Hain Celestial, Amazon.com, Whole Foods analyst commentary  »

Hain Celestial guidance…

HAIN

Hain Celestial

$32.66

-0.5 (-1.51%)

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

WFM

Whole Foods

$43.20

-0.06 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

GLNG

Golar LNG

$21.70

-0.06 (-0.28%)

07:43
06/23/17
06/23
07:43
06/23/17
07:43
Recommendations
Golar LNG analyst commentary  »

Golar LNG upcoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENOC

EnerNOC

$7.65

2.25 (41.67%)

07:43
06/23/17
06/23
07:43
06/23/17
07:43
Downgrade
EnerNOC rating change  »

EnerNOC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEJU

Leju

$2.46

0.07 (2.93%)

07:41
06/23/17
06/23
07:41
06/23/17
07:41
Downgrade
Leju rating change  »

Leju downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

07:41
06/23/17
06/23
07:41
06/23/17
07:41
Periodicals
Amazon files patent application for multi-level drone tower, BI reports »

Amazon is seeking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HAIN

Hain Celestial

$32.66

-0.5 (-1.51%)

07:38
06/23/17
06/23
07:38
06/23/17
07:38
Recommendations
Hain Celestial analyst commentary  »

Hain Celestial guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

GILD

Gilead

$70.48

2.98 (4.41%)

07:38
06/23/17
06/23
07:38
06/23/17
07:38
Hot Stocks
European CHMP adopts positive opinion for Gilead's Vosevi »

Gilead Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

GILD

Gilead

$70.48

2.98 (4.41%)

07:37
06/23/17
06/23
07:37
06/23/17
07:37
Initiation
Gilead initiated  »

Gilead initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

AKS

AK Steel

$6.30

0.11 (1.78%)

07:37
06/23/17
06/23
07:37
06/23/17
07:37
Technical Analysis
Technical View: AK Steel rises in pre-market, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

OCUL

Ocular Therapeutix

$11.54

0.5 (4.53%)

07:36
06/23/17
06/23
07:36
06/23/17
07:36
Downgrade
Ocular Therapeutix rating change  »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

QUIK

QuickLogic

07:35
06/23/17
06/23
07:35
06/23/17
07:35
Hot Stocks
QuickLogic collaborates with AISpeech »

QuickLogic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

BAC

Bank of America

$22.93

-0.2 (-0.86%)

, GE

General Electric

$27.55

-0.23 (-0.83%)

07:35
06/23/17
06/23
07:35
06/23/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BAC

Bank of America

$22.93

-0.2 (-0.86%)

GE

General Electric

$27.55

-0.23 (-0.83%)

SNAP

Snap

$17.64

0.37 (2.14%)

AKS

AK Steel

$6.30

0.11 (1.78%)

WLL

Whiting Petroleum

$5.14

-0.03 (-0.58%)

BX

Blackstone

$33.06

0.1 (0.30%)

FSLR

First Solar

$38.42

1.19 (3.20%)

TECK

Teck Resources

$15.88

0.58 (3.79%)

CSIQ

Canadian Solar

$15.07

1.08 (7.72%)

HZNP

Horizon Pharma

$11.87

0.44 (3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 19

    Jul

  • 25

    Jul

  • 02

    Oct

BBRY

BlackBerry

$11.06

0.41 (3.85%)

07:34
06/23/17
06/23
07:34
06/23/17
07:34
Technical Analysis
Technical View: BlackBerry falls after Q1 revenue misses consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

ESPR

Esperion

$42.31

1.29 (3.14%)

07:33
06/23/17
06/23
07:33
06/23/17
07:33
Initiation
Esperion initiated  »

Esperion initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

, BIIB

Biogen

$280.57

1.97 (0.71%)

07:33
06/23/17
06/23
07:33
06/23/17
07:33
Hot Stocks
Samsung Bioepis' Imrali recommended for approval by EMA »

Samsung Bioepis announced…

SSNLF

Samsung

BIIB

Biogen

$280.57

1.97 (0.71%)

ABBV

AbbVie

$73.18

1.84 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.